Iterum Therapeutics plc ITRM 深 滬
已收盤 09-05 16:00:00 美东时间
0.6782
+0.046
+7.31%
華盛通- 最 高0.6999
- 今 開0.632
- 成交量 49.29万股
- 最 低 0.632
- 昨 收 0.632
- 總市值 2712.80万
- 52周最高 3.02
- 市盈率 靜 --
- 換手率 1.23%
- 52周最低 0.6108
- 委 比 54.13%
- 總股本 4000.00万
- 歷史最高 195.00
- 量 比 0.79
- 振 幅 10.74%
- 歷史最低 0.6108
- 每 手 1
- 風險率 0.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Iterum Therapeutics Faces Nasdaq Delisting Notice
The latest update is out from Iterum Therapeutics ( ($ITRM) ). On August 25, 20...
08-29 05:00
Iterum Therapeutics Launches New Antibiotic ORLYNVAH
Iterum Therapeutics ( ($ITRM) ) has issued an update. On August 20, 2025, Iteru...
08-20 20:45
Iterum Therapeutics Announces U.S. Commercial Launch Of ORLYNVAH Oral Tablets
Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today
08-20 20:02
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
Iterum Therapeutics has commercially launched ORLYNVAH™, the first FDA-approved oral penem antibiotic for treating uncomplicated urinary tract infections (uUTIs) in adult women caused by certain bacteria. The drug offers a critical new option as antibiotic resistance increases, with 57% of initial infections resistant to at least one antibiotic class. ORLYNVAH™, approved in October 2024, provides a much-needed alternative for patients with limite...
08-20 12:00
CORRECTION: Iterum Therapeutics Q2 Adj. EPS $(0.13) Misses $(0.11) Estimate. Cash And Equivalents Of $13M, Runway Into 2026
Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 43.48 percent increase over losses of $(0.23) per share
08-05 20:49
Iterum Therapeutics Non-GAAP EPS of -$0.13
Iterum Therapeutics press release (NASDAQ:ITRM): Q2 Non-GAAP EPS of -$0.13. Cash and cash equivalents were $13.0 million as of June 30, 2025. Based on Iterum’s current operating plan, Iterum expects t...
08-05 19:16
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Insights Ahead: Iterum Therapeutics's Quarterly Earnings
Iterum Therapeutics (NASDAQ:ITRM) is preparing to release its quarterly earning...
08-05 05:03
Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025
Iterum Therapeutics plc, a company focused on developing next-generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens, announced it will release its second quarter 2025 financial results before the U.S. market opens on August 5, 2025. Management will host a conference call at 8:30 a.m. ET that day. To access the call, dial 833-470-1428 (domestic) or 404-975-4839 (international) with Access Code 740801. The ...
07-29 12:00
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Iterum Therapeutics授予新任首席商业化官Christine Coyne 20万股股票期权，行权价为每股0.97美元，期权有效期10年，分四年归属，每年25%。期权授予基于Nasdaq新员工激励规定，经薪酬委员会批准。Iterum专注于开发抗生素治疗耐药感染，其主要产品sulopenem已获FDA批准用于治疗尿路感染。
07-02 20:30
